Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis

Cancer Prevention Research

Volumn 2, Issue 4, 2009, Pages 330-337

  Gandhi, Leena ^a,b   McNamara, Kate L ^a   Li, Danan ^a   Borgman, Christa L ^a   McDermott, Ultan ^c   Brandstetter, Kathleyn A ^a   Padera, Robert F ^b   Chirieac, Lucian R ^b   Settleman, Jeffrey E ^c   Wong, Kwok Kin ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLACEBO; SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; KRAS2 PROTEIN, MOUSE; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; PYRROLE DERIVATIVE; STK11 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; GENE DELETION; GENE MUTATION; GENETIC ENGINEERING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOCAL METASTASIS; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; ANIMAL; DISEASE MODEL; GENETICS; LUNG TUMOR; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; IMMUNOHISTOCHEMISTRY; INDOLES; LUNG NEOPLASMS; MICE; MUTATION; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); PYRROLES;

EID: 67549102923     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0213     Document Type: Article

References (38)

1. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, IIIA. Chest 2000;117:374-379
2. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26: 4617-4625
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360 (Pubitemid 38101630)
4. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597 (Pubitemid 41007845)
5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7: 719-727 (Pubitemid 44283661)
6. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559
7. Fischer C, Jonckx B, Mazzone M, et al. Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-475
8. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
9. Timar J, Dome B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem 2008;8:462-469
10. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5:1280-1289 (Pubitemid 43881321)
11. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-233
12. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337 (Pubitemid 36109749)
13. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745 (Pubitemid 47338181)
14. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-1373 (Pubitemid 46450424)
15. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656 (Pubitemid 351264362)
16. Ji H, Houghton AM, Mariani TJ, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006;25:2105-2112
17. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006;9:485-495 (Pubitemid 43832191)
18. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-810 (Pubitemid 47266337)
19. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-4939 (Pubitemid 46910201)
20. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006;103:7817-7822 (Pubitemid 43752864)
21. Li D, Shimamura T, Ji H, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007;12:81-93. (Pubitemid 47001787)
22. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-3248 (Pubitemid 34008190)
23. Rasband WS. ImageJ. 1997-2008.
24. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International 2004;11:36-42.
25. Reinmuth N, Rensinghoff S, Raedel M, et al. Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells. Int J Oncol 2007;31:621-626
26. Zhang L, Hannay JA, Liu J, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006;66:8770-8778 (Pubitemid 44449194)
27. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007;4:e186. (Pubitemid 46998627)
28. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008;3:e3077.
29. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007;37:878-886 (Pubitemid 350029203)
30. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203 (Pubitemid 350235027)
31. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-146 (Pubitemid 37040829)
32. Du R, Lu KV, Petritsch C, et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-220 (Pubitemid 351318372)
33. Altorki N, Heymach J, Guarino M, et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-of-concept study. Annals of Oncology 2008;19:viii89-viii124.
34. Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005;65:5076-5083 (Pubitemid 40827316)
35. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-1478
36. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275
37. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23: 5900-5909
38. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17. (Pubitemid 40412734)